December 10, 2024
BURLINGTON, Ontario – December 9, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $6,000,000 of gross proceeds, consisting of up to 24,000,000 units (the...
December 5, 2024
BURLINGTON, Ontario – December 5, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company, is pleased to announce that it has filed a patent application for its Lidocaine Oral Thin Film Strip, with the Canadian Intellectual Property Office...
October 30, 2024
BURLINGTON, Ontario – October 30, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed a second and final tranche of its previously announced equity private placement financing (the “Financing”) for aggregate gross proceeds of...
October 1, 2024
BURLINGTON, Ontario – October 1, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...
September 16, 2024
BURLINGTON, Ontario – September 14, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated August 7, 2024, regarding a proposed equity private placement financing (the “Financing”), the Company has received an extension from...
August 26, 2024
BURLINGTON, Ontario – August 6, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that it has appointed Jason Lewis as a director of the Company, effective immediately. Mr. Lewis is Senior Vice President, Business Development, of RDT and was...
July 22, 2024
BURLINGTON, Ontario – July 18, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed a first tranche of its previously announced equity private placement financing (the “Financing”) for aggregate gross proceeds of $309,000. The...
July 2, 2024
BURLINGTON, Ontario – July 2, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...
July 2, 2024
Burlington, Ontario – June 28, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), is pleased to announce the filing of its financial results for the year ended February 29, 2024. Mark Upsdell, Chairman and Chief Executive Officer, stated, “Over the past...
June 25, 2024
Burlington, Ontario – June 25, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol DOSE is pleased to announce the recent award of a Mitacs Accelerate grant, with a value of $30,000 in May...